TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Roberts, Cai M ^a,b   Tran, Michelle A ^a,e   Pitruzzello, Mary C ^b   Wen, Wei ^c   Loeza, Joana ^d,f   Dellinger, Thanh H ^c   Mor, Gil ^b   Glackin, Carlotta A ^a  

^a Department of Developmental and Stem Cell Biology ^*  (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

^e RICE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GROWTH ARREST-SPECIFIC PROTEIN 6; HIGH MOBILITY GROUP A2 PROTEIN; NERVE CELL ADHESION MOLECULE L1; NUCLEAR PROTEIN; PROTEIN KINASE B; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, HUMAN;

ANIMAL; BIOLOGICAL MODEL; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN; GENETICS; HUMAN; METABOLISM; MOUSE; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; REPRODUCIBILITY; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HMGA2 PROTEIN; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MODELS, BIOLOGICAL; NEURAL CELL ADHESION MOLECULE L1; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REPRODUCIBILITY OF RESULTS; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TWIST-RELATED PROTEIN 1; UP-REGULATION;

EID: 84996520566     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep37652     Document Type: Article

References (51)

1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA: a cancer journal for clinicians 66, 7-30, doi: 10.3322/caac.21332 (2016).
2. Khalil, I., Brewer, M. A., Neyarapally, T. & Runowicz, C. D. The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. Gynecol Oncol 116, 282-285, doi: 10.1016/j.ygyno.2009.10.085 (2010).
3. Visintin, I. et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14, 1065-1072, doi: 10.1158/1078-0432. ccr-07-1569 (2008).
4. Alvero, A. B. et al. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo. Mol Cancer Ther 15, 1279-1290, doi: 10.1158/1535-7163.mct-16-0005 (2016).
5. Yin, G. et al. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29, 3545-3553, doi: 10.1038/onc.2010.111 (2010).
6. Bildsoe, H. et al. Requirement for Twist1 in frontonasal and skull vault development in the mouse embryo. Developmental biology 331, 176-188, doi: 10.1016/j.ydbio.2009.04.034 (2009).
7. Simpson, P. Maternal-Zygotic Gene Interactions during Formation of the Dorsoventral Pattern in Drosophila Embryos. Genetics 105, 615-632 (1983).
8. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939, doi: 10.1016/j.cell.2004.06.006 [doi] S0092867404005768 [pii] (2004).
9. Fu, J. et al. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res 21, 275-289, doi: cr2010118 [pii] 10.1038/cr.2010.118 [doi] (2011).
10. Vesuna, F., Lisok, A., Kimble, B. & Raman, V. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 11, 1318-1328 (2009).
11. Finlay, J. et al. Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine: nanotechnology, biology, and medicine 11, 1657-1666, doi: 10.1016/j.nano.2015.05.011 (2015).
12. Maestro, R. et al. Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13, 2207-2217 (1999).
13. Yin, G. et al. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene 32, 39-49, doi: onc201233 [pii] 10.1038/onc.2012.33 [doi] (2013).
14. Chappell, N. P. et al. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. J Proteome Res 11, 4605-4614, doi: 10.1021/pr300403d [doi] (2012).
15. Wang, Y. et al. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 56, 365-375, doi: S1043-4666(11)00182-7 [pii] 10.1016/j.cyto.2011.06.005 [doi] (2011).
16. Laios, A. et al. Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. Int J Mol Sci 14, 2085-2103, doi: ijms14012085 [pii] 10.3390/ijms14012085 [doi] (2013).
17. Villavicencio, E. H. et al. Cooperative E-box regulation of human GLI1 by TWIST and USF. Genesis 32, 247-258 (2002).
18. Kudo, K. et al. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene 31, 4718-4724, doi: onc2011610 [pii] 10.1038/onc.2011.610 [doi] (2012).
19. Cheng, G. Z. et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67, 1979-1987, doi: 67/5/1979 [pii] 10.1158/0008-5472.CAN-06-1479 [doi] (2007).
20. Shiota, M. et al. Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells. BJU international 108, E142-149, doi: 10.1111/j.1464-410X.2010.09810.x (2011).
21. Ahmed, N., Abubaker, K., Findlay, J. & Quinn, M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 10, 268-278 (2010).
22. Wang, T. et al. Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3beta signaling pathway. Oncology letters 7, 1102-1108, doi: 10.3892/ol.2014.1816 (2014).
23. Brown, C. E. et al. Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res 69, 8886-8893, doi: 10.1158/0008-5472.can-09-2687 (2009).
24. Finlay, J. et al. RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis. BioMed research international 2015, 382745, doi: 10.1155/2015/382745 (2015).
25. Li, S. et al. TWIST1 associates with NF-kappaB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production. BMC Biol 10, 73, doi: 1741-7007-10-73 [pii] 10.1186/1741-7007-10-73 [doi] (2012).
26. Borrmann, L. et al. High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res 31, 6841-6851 (2003).
27. Lee, W. P., Wen, Y., Varnum, B. & Hung, M. C. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21, 329-336, doi: 10.1038/sj.onc.1205066 (2002).
28. Jung, J. et al. The cell adhesion molecule L1 promotes gallbladder carcinoma progression in vitro and in vivo. Oncol Rep 25, 945-952, doi: 10.3892/or.2011.1181 (2011).
29. Lin, Y. et al. MicroRNA-33b Inhibits Breast Cancer Metastasis by Targeting HMGA2, SALL4 and Twist1. Scientific reports 5, 9995, doi: 10.1038/srep09995 (2015).
30. Demarchi, F., Verardo, R., Varnum, B., Brancolini, C. & Schneider, C. Gas6 anti-apoptotic signaling requires NF-kappa B activation. J Biol Chem 276, 31738-31744, doi: 10.1074/jbc.M104457200 (2001).
31. Melaragno, M. G. et al. Gas6 inhibits apoptosis in vascular smooth muscle: role of Axl kinase and Akt. Journal of molecular and cellular cardiology 37, 881-887, doi: 10.1016/j.yjmcc.2004.06.018 (2004).
32. Gjerdrum, C. et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 107, 1124-1129, doi: 10.1073/pnas.0909333107 (2010).
33. Sharif, M. N. et al. Twist mediates suppression of inflammation by type I IFNs and Axl. The Journal of experimental medicine 203, 1891-1901, doi: 10.1084/jem.20051725 (2006).
34. Buehler, M. et al. Meta-analysis of microarray data identifies GAS6 expression as an independent predictor of poor survival in ovarian cancer. BioMed research international 2013, 238284, doi: 10.1155/2013/238284 (2013).
35. Rankin, E. B. et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res 70, 7570-7579, doi: 10.1158/0008-5472.can-10-1267 (2010).
36. Kiefel, H. et al. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NFkappaB activation. Carcinogenesis 33, 1919-1929, doi: 10.1093/carcin/bgs220 (2012).
37. Weinspach, D. et al. Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. Clin Exp Metastasis 31, 87-100, doi: 10.1007/s10585-013-9613-6 (2014).
38. Lund, K. et al. Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PloS one 10, e0123684, doi: 10.1371/journal.pone.0123684 (2015).
39. Pfeifer, M. et al. L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC molecular biology 11, 64, doi: 10.1186/1471-2199-11-64 (2010).
40. Schafer, H. et al. TGF-beta1-dependent L1CAM expression has an essential role in macrophage-induced apoptosis resistance and cell migration of human intestinal epithelial cells. Oncogene 32, 180-189, doi: 10.1038/onc.2012.44 (2013).
41. Sebens Muerkoster, S. et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 26, 2759-2768, doi: 10.1038/sj.onc.1210076 (2007).
42. Stoeck, A. et al. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol 104, 461-469, doi: 10.1016/j.ygyno.2006.08.038 (2007).
43. Dellinger, T. H. et al. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA). Gynecol Oncol 141, 336-340, doi: 10.1016/j.ygyno.2016.02.003 (2016).
44. Abdel Azim, S. et al. Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer. Oncotarget, doi: 10.18632/oncotarget.9291 (2016).
45. Hahne, J. C. et al. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Oncol Rep 28, 2023-2028, doi: 10.3892/or.2012.2041 [doi] (2012).
46. Domcke, S., Sinha, R., Levine, D. A., Sander, C. & Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4, 2126, doi: 10.1038/ncomms3126 (2013).
47. Imani, S., Hosseinifard, H., Cheng, J., Wei, C. & Fu, J. Prognostic Value of EMT-inducing Transcription Factors (EMT-TFs) in Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Scientific reports 6, 28587, doi: 10.1038/srep28587 (2016).
48. Yoon, N. A. et al. Tristetraprolin suppresses the EMT through the down-regulation of Twist1 and Snail1 in cancer cells. Oncotarget 7, 8931-8943, doi: 10.18632/oncotarget.7094 (2016).
49. Cao, H. H. et al. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma. Scientific reports 6, 21731, doi: 10.1038/srep21731 (2016).
50. Artymovich, K. & Appledorn, D. M. A multiplexed method for kinetic measurements of apoptosis and proliferation using livecontent imaging. Methods Mol Biol 1219, 35-42, doi: 10.1007/978-1-4939-1661-0-4 (2015).
51. Craveiro, V. et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer medicine 2, 751-762, doi: 10.1002/cam4.115 (2013).